Year in Review: Novel Insights in the Pathogenesis of Spondyloarthritis - SPARTAN 2024 Annual Meeting Proceedings

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2024 Dec 28

PMID 39731620

Authors

Patricia Remalante-Rayco

Akihiro Nakamura

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The canonical pathogenesis of spondyloarthritis (SpA) involves inflammation driven by HLA-B27, type 3 immunity, and gut microbial dysregulation. This review based on information presented at the SPARTAN meeting highlights studies on the pathogenesis of SpA from the past year, focusing on emerging mechanisms such as the roles of microbe-derived metabolites, microRNAs (miRNAs) and cytokines in plasma exosomes, specific T cell subsets, and neutrophils.

Recent Findings: The induction of arthritis in a preclinical model through microbiota-driven alterations in tryptophan catabolism provides new insights as to how intestinal dysbiosis may activate disease via the gut-joint axis. Immune activation may likewise be modulated by dysregulated miRNAs and cytokines contained in plasma exosomes, which appear to influence the homeostasis of both effector T cells and regulatory T cells (Tregs). Closer examination of T cells in animal models has uncovered distinct transcriptional and functional profiles between gut and joint Tregs, as well as highly specific T cell subsets that can be targeted to induce disease modification. Newer studies including both SpA patients and preclinical models have focused on the key role of neutrophils as drivers of inflammation and new bone formation in hypoxic, inflammation-driven tissue environments, potentially through interactions with adipocytes and mesenchymal stem cells. Functional studies and high-throughput techniques using samples from SpA patients and preclinical models have significantly enhanced our understanding of SpA pathogenesis, offering new insights into the specific mechanisms of immune regulation and identifying promising therapeutic targets.

References

Nakamura A, Boroojeni S, Haroon N . Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis. Semin Immunopathol. 2021; 43(2):245-253. DOI: 10.1007/s00281-020-00833-w. View

Nakamura A, Haroon N . Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis. Curr Rheumatol Rep. 2021; 23(5):31. DOI: 10.1007/s11926-021-00995-y. View

Van Praet L, Jacques P, Van den Bosch F, Elewaut D . The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol. 2012; 8(5):288-95. DOI: 10.1038/nrrheum.2012.42. View

Mauro D, Nakamura A, Haroon N, Ciccia F . The gut-enthesis axis and the pathogenesis of Spondyloarthritis. Semin Immunol. 2022; 58:101607. DOI: 10.1016/j.smim.2022.101607. View

Choi S, Brown J, Gong M, Ge Y, Zadeh M, Li W . Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice. Sci Transl Med. 2020; 12(551). PMC: 7739186. DOI: 10.1126/scitranslmed.aax2220. View

Luo Y, Tong Y, Wu L, Niu H, Li Y, Su L . Alteration of Gut Microbiota in Individuals at High-Risk for Rheumatoid Arthritis Associated With Disturbed Metabolome and the Initiation of Arthritis Through the Triggering of Mucosal Immunity Imbalance. Arthritis Rheumatol. 2023; 75(10):1736-1748. DOI: 10.1002/art.42616. View

Motta F, Carena M, Selmi C, Vecellio M . MicroRNAs in ankylosing spondylitis: Function, potential and challenges. J Transl Autoimmun. 2020; 3:100050. PMC: 7388379. DOI: 10.1016/j.jtauto.2020.100050. View

Huang Y, Feng F, Huang Q, Zheng S, Huang Z, Deng W . Proteomic analysis of serum-derived extracellular vesicles in ankylosing spondylitis patients. Int Immunopharmacol. 2020; 87:106773. DOI: 10.1016/j.intimp.2020.106773. View

Wielinska J, Crossland R, Lacina P, Swierkot J, Bugaj B, Dickinson A . Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors. Dis Markers. 2021; 2021:2924935. PMC: 8529175. DOI: 10.1155/2021/2924935. View

10.

Tavasolian F, Lively S, Pastrello C, Tang M, Lim M, Pacheco A . Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis. Ann Rheum Dis. 2023; 82(11):1429-1443. DOI: 10.1136/ard-2022-223791. View

11.

Mahnke J, Schumacher V, Ahrens S, Kading N, Feldhoff L, Huber M . Interferon Regulatory Factor 4 controls T cell effector function and metabolism. Sci Rep. 2016; 6:35521. PMC: 5071867. DOI: 10.1038/srep35521. View

12.

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

13.

Sieper J, Poddubnyy D, Miossec P . The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019; 15(12):747-757. DOI: 10.1038/s41584-019-0294-7. View

14.

Venken K, Jarlborg M, Decruy T, Mortier C, Vlieghe C, Gilis E . Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis. Ann Rheum Dis. 2023; 82(8):1076-1090. DOI: 10.1136/ard-2022-223757. View

15.

Haroon N, Inman R, Learch T, Weisman M, Lee M, Rahbar M . The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013; 65(10):2645-54. PMC: 3974160. DOI: 10.1002/art.38070. View

16.

Ornbjerg L, Brahe C, Askling J, Ciurea A, Mann H, Onen F . Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Ann Rheum Dis. 2019; 78(11):1536-1544. DOI: 10.1136/annrheumdis-2019-215427. View

17.

Britanova O, Lupyr K, Staroverov D, Shagina I, Aleksandrov A, Ustyugov Y . Targeted depletion of TRBV9 T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023; 29(11):2731-2736. PMC: 10667094. DOI: 10.1038/s41591-023-02613-z. View

18.

Chiocchia G, Boissier M, Fournier C . Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies. Eur J Immunol. 1991; 21(12):2899-905. DOI: 10.1002/eji.1830211202. View

19.

Liu Z, Cort L, Eberwine R, Herrmann T, Leif J, Greiner D . Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vβ13 as a therapeutic target and biomarker. Diabetes. 2012; 61(5):1160-8. PMC: 3331757. DOI: 10.2337/db11-0867. View

20.

Maciocia P, Wawrzyniecka P, Philip B, Ricciardelli I, Akarca A, Onuoha S . Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12):1416-1423. DOI: 10.1038/nm.4444. View